Rahika (Capmatinib): A Targeted Therapy for Advanced Lung Cancer

Rahika (Capmatinib) is a precision-targeted therapy designed for the treatment of certain types of advanced or metastatic non-small cell lung cancer (NSCLC). It is a MET inhibitor that addresses cancer with specific genetic mutations, providing a tailored approach to therapy.

Composition

• Active Ingredient: Capmatinib
• Available Strengths: 150mg, 200mg tablets (adjust based on product specifications)

Capmatinib is a selective inhibitor of the MET receptor tyrosine kinase. The MET pathway is often overactivated in cancers due to genetic alterations such as exon 14 skipping mutations. By inhibiting this pathway, Capmatinib reduces tumor growth, spread, and survival.

Uses

1. Non-Small Cell Lung Cancer (NSCLC): Specifically for patients with tumors harboring MET exon 14 skipping mutations as detected by an FDA-approved test.
2. Metastatic NSCLC: Used as first-line therapy or in cases where other treatments have failed.

Rahika (Capmatinib) is a groundbreaking targeted therapy for patients with MET exon 14 skipping mutation-positive NSCLC. Its precision mechanism and potential to improve outcomes make it an essential tool in oncology. Close monitoring and adherence to prescribed regimens are crucial for maximizing its benefits and minimizing risks.

Side Effects

Common Side Effects:

• Nausea
• Fatigue
• Vomiting
• Peripheral edema
• Decreased appetite

Serious Side Effects:

• Interstitial Lung Disease (ILD): Rare but potentially life-threatening. Discontinue if diagnosed.
• Liver Toxicity: Monitor liver enzymes regularly.
• Photosensitivity: Advise patients to avoid prolonged sun exposure and use sun protection.

Precautions

1. Liver Function: Routine testing of liver enzymes (ALT, AST, and bilirubin) is necessary.
2. Interstitial Lung Disease: Patients should report new or worsening respiratory symptoms.
3. Photosensitivity: Use sunscreen and protective clothing outdoors.
4. Drug Interactions: Capmatinib may interact with CYP3A4 inhibitors or inducers. Inform your doctor about all medications being taken.
5. Pregnancy and Breastfeeding: Contraindicated due to potential harm to the fetus or infant. Effective contraception is advised during treatment and for 1 week after the last dose.

Contraindications

• Known hypersensitivity to Capmatinib or any excipients.
• Severe liver impairment unless the benefit outweighs the risk.

Monitoring

• Liver Function Tests: Regular monitoring is required to detect hepatotoxicity early.
• Pulmonary Symptoms: Evaluate promptly to rule out ILD or pneumonitis.
• Electrolyte Levels: Ensure balance, especially in patients with prior comorbidities.

Dosage and Administration

• Recommended Dose: Typically 400mg taken orally twice daily.
• Route: Oral, with or without food.
• Duration: Treatment continues until disease progression or unacceptable toxicity occurs.

Storage

• Store at 15°C–25°C (59°F–77°F).
• Protect from moisture and keep the bottle tightly closed.
• Keep out of reach of children.